Celularity Inc. Share Price & Technical Analysis
CELU · $1.06 (+3.92%)
Healthcare / Biotechnology
$1.06
+3.92%
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's…
Price chart
Seasonality
Jun has 0 positive and 3 negative years (last 5 years shown)
0% return in Jun, -14% avg return in past 3 year Jun month.
-13% return in 2026, -33% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 9% | 0% | 8% | -31% | 0% | 0% | – | – | – | – | – | – | -13% |
| 25 | -5% | -43% | 55% | -12% | 40% | -9% | 65% | 18% | -32% | -5% | 5% | -45% | 33% |
| 24 | 52% | -12% | 41% | -43% | 3% | 0% | -3% | -3% | 3% | -50% | 33% | 5% | 26% |
| 23 | -31% | -21% | -11% | -6% | 25% | -32% | -27% | -24% | -35% | 0% | -9% | 14% | -158% |
| 22 | -12% | 60% | 20% | 34% | -18% | -64% | -7% | -13% | -13% | 0% | -27% | -29% | -69% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$30.10M
P/E ratio
—
52W high
$4.35
52W low
$0.71
Volume
36,268
Beta
0.45
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Celularity Inc. share price today?
- Celularity Inc. (CELU) last traded around $1.06 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does CELU have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for CELU. Download the app for real-time alerts.
- How can I analyze Celularity Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.